Nature Communications publication on SARS-CoV-2 vaccine development by Immunetune

Aug 3, 2022

Immunetune’s development of a vaccine against SARS-CoV-2 has been published as part of a consortium in Nature Communications in July 2022. In this specific publication, named ‘A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection‘, results indicate that vaccination with a single T cell epitope protected animals against a lethal infection of SARS-CoV-2. Such T cell vaccines are able to target more proteins and are less prone to mutations by the virus as compared to current coronavirus vaccines that primarily induce antibodies. These findings are part of Immunetune’s development of a pan-coronavirus DNA vaccine in collaboration with the LUMC in the Netherlands. 
The LUMC has also described the results in a separate press release titled ‘T-cells more important in the fight against the COVID-19 virus than initially thought’, which can be found here.